S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item

AIM ImmunoTech (AIM) Competitors

$0.56
-0.05 (-8.17%)
(As of 04/12/2024 ET)

AIM vs. PMCB, ZIVO, SABS, SRZN, APTO, TCON, SNTI, EVAX, IKT, and CRTX

Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include PharmaCyte Biotech (PMCB), ZIVO Bioscience (ZIVO), SAB Biotherapeutics (SABS), Surrozen (SRZN), Aptose Biosciences (APTO), TRACON Pharmaceuticals (TCON), Senti Biosciences (SNTI), Evaxion Biotech A/S (EVAX), Inhibikase Therapeutics (IKT), and Cortexyme (CRTX). These companies are all part of the "medical" sector.

AIM ImmunoTech vs.

PharmaCyte Biotech (NASDAQ:PMCB) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 1.0% of PharmaCyte Biotech shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PharmaCyte Biotech has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PharmaCyte Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
AIM ImmunoTech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, PharmaCyte Biotech and PharmaCyte Biotech both had 3 articles in the media. PharmaCyte Biotech's average media sentiment score of 0.56 beat AIM ImmunoTech's score of 0.29 indicating that AIM ImmunoTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PharmaCyte Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AIM ImmunoTech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PharmaCyte Biotech has higher earnings, but lower revenue than AIM ImmunoTech. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharmaCyte BiotechN/AN/A-$4.32M-$1.20-1.86
AIM ImmunoTech$200K140.22-$28.96M-$0.60-0.94

PharmaCyte Biotech has a net margin of 0.00% compared to PharmaCyte Biotech's net margin of -14,337.62%. AIM ImmunoTech's return on equity of -9.69% beat PharmaCyte Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
PharmaCyte BiotechN/A -9.69% -5.86%
AIM ImmunoTech -14,337.62%-121.69%-97.91%

AIM ImmunoTech received 56 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
PharmaCyte BiotechN/AN/A
AIM ImmunoTechOutperform Votes
56
82.35%
Underperform Votes
12
17.65%

Summary

PharmaCyte Biotech and AIM ImmunoTech tied by winning 6 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIM vs. The Competition

MetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$28.04M$2.65B$4.88B$17.32B
Dividend YieldN/A2.25%2.93%3.53%
P/E Ratio-0.9444.71258.1225.08
Price / Sales140.22344.822,402.409.09
Price / CashN/A153.0437.0517.56
Price / Book2.814.064.605.09
Net Income-$28.96M-$38.92M$103.90M$972.03M
7 Day Performance14.18%-2.53%-2.32%-2.61%
1 Month Performance68.52%0.20%-0.35%-0.22%
1 Year Performance23.54%16.04%14.38%114.25%

AIM ImmunoTech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMCB
PharmaCyte Biotech
0 of 5 stars
$2.48
+1.6%
N/A-24.9%$20.96MN/A-2.072Short Interest ↑
ZIVO
ZIVO Bioscience
0 of 5 stars
$7.50
flat
N/A-55.0%$20.85M$30,000.00-1.638
SABS
SAB Biotherapeutics
2.0801 of 5 stars
$4.50
+4.9%
$15.50
+244.4%
+516.0%$23.54M$23.90M0.0056Short Interest ↑
Gap Up
SRZN
Surrozen
2.5419 of 5 stars
$9.47
-6.2%
N/A+5.4%$19.32M$12.50M-0.5474Short Interest ↑
Gap Down
High Trading Volume
APTO
Aptose Biosciences
1.7023 of 5 stars
$1.58
-1.3%
$19.80
+1,153.2%
-82.4%$24.84MN/A-0.2031Short Interest ↑
TCON
TRACON Pharmaceuticals
1.3798 of 5 stars
$0.42
flat
$4.00
+862.5%
-94.1%$18.91M$12.05M-1.6017Stock Split
Short Interest ↓
SNTI
Senti Biosciences
2.6146 of 5 stars
$0.35
-5.4%
$6.00
+1,619.2%
-68.4%$15.97M$2.56M-0.2248Positive News
Gap Down
EVAX
Evaxion Biotech A/S
2.6636 of 5 stars
$3.88
+20.1%
$14.00
+260.8%
-66.1%$15.71M$70,000.00-0.5763Gap Down
IKT
Inhibikase Therapeutics
1.0319 of 5 stars
$2.15
-0.5%
$27.00
+1,155.8%
-37.1%$13.93M$260,000.00-0.606Gap Down
CRTX
Cortexyme
0 of 5 stars
$1.05
-3.7%
N/A-38.6%$31.66MN/A-0.3555Gap Down

Related Companies and Tools

This page (NYSE:AIM) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners